Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

COVID-19 in Patients with Systemic Inflammatory Diseases: Impact on Disease Activity

Author(s): Saoussen Miledi, Sirine Bouzid*, Alia Fazaa, Mariem Sallemi, Hiba Bousaa, Kaouther Ben Abdelghani and Ahmed Laatar

Volume 19, Issue 3, 2023

Published on: 07 February, 2023

Page: [330 - 335] Pages: 6

DOI: 10.2174/1573397119666230116151541

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Introduction: COVID-19 pandemic, an international emergency, raised concerns about the interaction of this infection and disease-modifying drugs used in the treatment of Systemic inflammatory diseases (SID). Understanding the relationship between COVID-19 and disease activity is crucial to adapt the treatment.

Aim: The aim of our study was to determine the impact of COVID-19 on the disease activity of rheumatic diseases.

Patients and Methods: We performed a cross-sectional study, including patients with SID (rheumatoid arthritis (RA) and spondyloarthritis (SpA)). Disease activity was evaluated during the last check-up before COVID-19 and within the period of 6 months after the infection. Activity scores were assessed with Disease Activity Score (DAS28) for RA and Ankylosing Spondylitis Disease Activity Score (ASDAS) for SpA. Correlation and regression coefficients were used to evaluate associations among the variables.

Results and Discussion: Totally, thirty-two patients were included; twenty followed for RA and twelve for axial SpA. The mean disease duration of the underlying rheumatic disease was 10.2 years (2-30). RA was seropositive and erosive in 61% and 31%, respectively. Seventeen patients were on csDMARDs: 14 were on Methotrexate and three patients were on Salazopyrine. Ten patients (31%) were treated with bDMARDs; Tumor necrosis factor (TNF)-alpha inhibitors were used in eight cases. Rituximab and secukinumab were prescribed for one patient each. In 70%, COVID-19 was pauci-symptomatic. A severe form with a need for hospitalization was noted in 9%. Two patients were admitted to the intensive care unit (ICU).

Overall, treatment with DMARDs was interrupted in all cases: when COVID-19 symptoms began in 82% and when PCR was positive in 18%. Both RA and axial SpA were not active after a mean period of 6 months after COVID-19 infection (p = 0.818 and p = 0.626, respectively).

Conclusion: Although our patients interrupted their DMARDs, our study demonstrates that disease activity as assessed by ASDAS and DAS28 in SpA and RA remained unchanged after COVID-19.

Keywords: COVID-19, systemic inflammatory diseases, disease activity, rheumatic diseases, ankylosing spondylitis disease, methotrexate.

« Previous Next »
Graphical Abstract

[1]
Rajkumar RP. COVID-19 and mental health: A review of the existing literature. Asian J Psychiatr 2020; 52: 102066.
[http://dx.doi.org/10.1016/j.ajp.2020.102066] [PMID: 32302935]
[2]
Sveaas SH, Berg IJ, Provan SA, Semb AG, Hagen KB, Vøllestad N. Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: A randomized controlled pilot study. Randomized Controlled Trial 2014; 9(9): e108688.
[http://dx.doi.org/10.1371/journal.pone.0108688] [PMID: 4182541]
[3]
Roux CH, Brocq O, Gerald F, Pradier C, Bailly L. Impact of home confinement during the COVID‐19 pandemic on medication use and disease activity in spondyloarthritis patients. Arthritis Rheumatol 2020; 72(10): 1771-2.
[http://dx.doi.org/10.1002/art.41397] [PMID: 32779880]
[4]
Ordinance on measures to combat the coronavirus (COVID-19) (COVID-19 Ordinance 2). The Swiss Federal Council 2020. Available from: https://www.fedlex.admin.ch/eli/cc/2020/141/en
[5]
Landewé RBM, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020; 79(7): 851-8.
[http://dx.doi.org/10.1136/annrheumdis-2020-217877] [PMID: 32503854]
[6]
Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID‐19 pandemic: Version 3. Arthritis Rheumatol 2021; 73(2): e1-e12.
[http://dx.doi.org/10.1002/art.41596] [PMID: 33277981]
[7]
Ciurea A, Papagiannoulis E, Bürki K, et al. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: Results from the swiss clinical quality management cohort. Ann Rheum Dis 2021; 80(2): 238-41.
[http://dx.doi.org/10.1136/annrheumdis-2020-218705] [PMID: 32963052]
[8]
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7): 934-43.
[http://dx.doi.org/10.1001/jamainternmed.2020.0994] [PMID: 32167524]
[9]
Nuño L, Novella NM, Bonilla G, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis 2020; 79(12): 1659-61.
[http://dx.doi.org/10.1136/annrheumdis-2020-218054] [PMID: 32606046]
[10]
Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-5.
[http://dx.doi.org/10.1016/j.ijid.2020.03.017] [PMID: 32173574]
[11]
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020; 323(20): 2052-9.
[http://dx.doi.org/10.1001/jama.2020.6775] [PMID: 32320003]
[12]
Burner TW, Rosenthal AK. Diabetes and rheumatic diseases. Curr Opin Rheumatol 2009; 21(1): 50-4.
[http://dx.doi.org/10.1097/BOR.0b013e32831bc0c4] [PMID: 19077719]
[13]
Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17(5): 729-52.
[http://dx.doi.org/10.1016/S1521-6942(03)00041-X] [PMID: 12915155]
[14]
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID ‐19. Am J Hematol 2020; 95(7): 834-47.
[http://dx.doi.org/10.1002/ajh.25829] [PMID: 32282949]
[15]
Liu Z, Long W, Tu M, et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect 2020; 81(2): 318-56.
[http://dx.doi.org/10.1016/j.jinf.2020.03.054] [PMID: 32283159]
[16]
Fisman DN, Tuite AR. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.07.05.21260050]
[17]
Day M. COVID-19: European drugs agency to review safety of ibuprofen. BMJ 2020; 368: m1168.
[http://dx.doi.org/10.1136/bmj.m1168] [PMID: 32205306]
[18]
FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. FDA 2020. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-advisespatients-use-non-steroidal-anti-inflammatory-drugs-nsaids-COVID-19#:~:text=Safety%20and%20Availability-,FDA%20advises%20patients%20on%20use%20of%20non%2Dsteroidal%20anti%2Dinflammatory,(NSAIDs)%20for%20COVID%2D19&text=%5B3%2F19%2F2020%5D,disease%20(COVID%2D19).
[19]
FitzGerald GA. Misguided drug advice for COVID-19. Science 2020; 367(6485): 1434.
[http://dx.doi.org/10.1126/science.abb8034] [PMID: 32198292]
[20]
Moore N, Bosco-Levy P, Thurin N, Blin P, Droz-Perroteau C. NSAIDs and COVID-19: A systematic review and meta-analysis. Drug Saf 2021; 44(9): 929-38.
[http://dx.doi.org/10.1007/s40264-021-01089-5] [PMID: 34339037]
[21]
Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: A prospective cohort study. Infect Dis Ther 2021; 10(1): 253-68.
[http://dx.doi.org/10.1007/s40121-020-00363-w] [PMID: 33135113]
[22]
Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97(5): 829-38.
[http://dx.doi.org/10.1016/j.kint.2020.03.005] [PMID: 32247631]
[23]
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5(7): 802-10.
[http://dx.doi.org/10.1001/jamacardio.2020.0950] [PMID: 32211816]
[24]
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2020; 79(7): 859-66.
[http://dx.doi.org/10.1136/annrheumdis-2020-217871]
[25]
Yuan M, Xu X, Xia D, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: A propensity score-based analysis. Shock 2020; 54(5): 638-43.
[http://dx.doi.org/10.1097/SHK.0000000000001574] [PMID: 32496422]
[26]
Qin X, Qiu S, Yuan Y, Zong Y, Tuo Z, Li J. Clinical characteristics and treatment of patients infected with COVID-19 in Shishou. China: Social Science Research Network 2020.
[http://dx.doi.org/10.2139/ssrn.3541147]
[27]
Maia R, Melo L, Mendes JJ, Freitas PT. Corticosteroids in COVID-19: A double-edged sword – a retrospective study. Med Intensiv 2022; 46(4): 229-31.
[http://dx.doi.org/10.1016/j.medin.2021.02.001] [PMID: 33744019]
[28]
Ebrahimi CF, Pourafkari L, Ebrahimi CAA, Nader ND. Effects of corticosteroids on COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Pulm Pharmacol Ther 2022; 72: 102107.
[http://dx.doi.org/10.1016/j.pupt.2021.102107] [PMID: 34933068]
[29]
Ibrahim A, Ahmed M, Conway R, Carey JJ. Risk of infection with methotrexate therapy in inflammatory diseases: A systematic review and meta-analysis. J Clin Med 2018; 8(1): 15.
[http://dx.doi.org/10.3390/jcm8010015] [PMID: 30583473]
[30]
Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007; 46(7): 1157-60.
[http://dx.doi.org/10.1093/rheumatology/kem076] [PMID: 17478469]
[31]
Conticini E, Bargagli E, Bardelli M, et al. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Ann Rheum Dis 2021; 80(2): e14-4.
[http://dx.doi.org/10.1136/annrheumdis-2020-217681] [PMID: 32414804]
[32]
Jones ME, Kohn AH, Pourali SP, et al. The use of biologics during the COVID-19 pandemic. Dermatol Clin 2021; 39(4): 545-53.
[http://dx.doi.org/10.1016/j.det.2021.05.010] [PMID: 34556244]
[33]
D’Silva KM, Wallace ZS. COVID-19 and disease-modifying anti-rheumatic drugs. Curr Rheumatol Rep 2021; 23(5): 28.
[http://dx.doi.org/10.1007/s11926-021-00998-9] [PMID: 33893890]
[34]
Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020; 19(5): 102523.
[http://dx.doi.org/10.1016/j.autrev.2020.102523] [PMID: 32205186]
[35]
Molto A, Gossec L, Meghnathi B, et al. An assessment in Spondyloarthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Ann Rheum Dis 2018; 77(1): 124-7.
[http://dx.doi.org/10.1136/annrheumdis-2017-212178] [PMID: 29038299]
[36]
Park JK, Kim MJ, Choi Y, Winthrop K, Song YW, Lee EB. Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: Post-hoc analysis of two randomized trials. Clin Rheumatol 2020; 39(2): 375-9.
[http://dx.doi.org/10.1007/s10067-019-04857-y] [PMID: 31823141]
[37]
Abhishek A, Boyton RJ, Peckham N, et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): A randomised, open label, superiority trial. Lancet Respir Med 2022; 10(9): 840-50.
[http://dx.doi.org/10.1016/S2213-2600(22)00186-2] [PMID: 35772416]
[38]
Fernández-Ávila DG, Barahona-Correa J, Romero-Alvernia D, et al. Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. Rheumatol Int 2022; 42(1): 41-9.
[http://dx.doi.org/10.1007/s00296-021-05014-y] [PMID: 34739574]
[39]
Barbhaiya M, Levine JM, Bykerk VP, Jannat-Khah D, Mandl LA. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann Rheum Dis 2021; 80(10): 1352-4.
[http://dx.doi.org/10.1136/annrheumdis-2021-220732] [PMID: 34158370]
[40]
Terracina KA, Tan FK. Flare of rheumatoid arthritis after COVID-19 vaccination. Lancet Rheumatol 2021; 3(7): e469-70.
[http://dx.doi.org/10.1016/S2665-9913(21)00108-9] [PMID: 33817664]

Rights & Permissions Print Cite
Article Metrics
62
2
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy